Verve Therapeutics, Inc. (NASDAQ:VERV) Receives $25.75 Average Price Target from Brokerages
Verve Therapeutics, Inc. (NASDAQ:VERV – Get Free Report) has received a consensus recommendation of “Buy” from the six analysts that are presently covering the firm, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 12-month target price among brokers that have issued a report on the stock in the […]
Verve Therapeutics, Inc. (NASDAQ:VERV – Get Free Report) has received a consensus recommendation of “Buy” from the six analysts that are presently covering the firm, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 12-month target price among brokers that have issued a report on the stock in the […]